Pharmacy compounding group webinar covers six PCAC-recommended peptides
The one-hour session reviews BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax and what each still needs for 503A eligibility.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 25 06:01 ETSource: Alliance for Pharmacy Compounding
The wire
- 01The Alliance for Pharmacy Compounding is offering a one-hour continuing education webinar, Peptides at the 503A Crossroads, reviewing the six peptides recommended by PCAC, priced at $75 or less for members.
- 02Pharmacists fielding BPC-157 and TB-500 questions get a structured review of proposed uses, dosage forms, dosing considerations, adverse effects, interactions, monitoring and regulatory status.
- 03Presenter Jim LaValle chairs the International Peptide Society; the session is an educational product, not a regulatory change, and none of the six peptides is yet eligible for 503A compounding.
From the source
Read at a4pc.orgWebinar: A clinical guide to the peptides your patients are asking about
If patients or prescribers have asked you about BPC-157 or TB-500 lately, you're not alone. Interest in peptides keeps growing, and pharmacists are often the ones fielding the questions.
